Washington state has announced updates to its drug formulary, effective January 1, 2022. The following is a list of updated drugs and therapeutic classes (or class codes) and their status on the Washington State Department of Labor and Industries outpatient formulary.
- beclomethasone dipropionate (Qvar RediHaler), budesonide suspension for nebulization (Pulmicort), fluticasone propionate (Flovent Diskus/HFA), and budesonide/formoterol fumarate (Symbicort) now require authorization with coverage based on acceptance of pulmonary condition
- antiretrovirals now require prior authorization except for the following agents: darunavir, darunavir/cobicistat, dolutegravir, elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil, emtricitabine, emtricitabine/tenofovir disoproxil, emtricitabine/rilpivirine/tenofovir disoproxil, lamivudine, raltegravir, rilpivirine, ritonavir, tenofovir disoproxil, zidovudine
Mitchell Pharmacy Solutions will work with our clients to identify impacted claimants and assist with formulary change notifications as needed.
For more information, please see the updated preferred drug list for additional information and exceptions.